VBS Fellows’ Foray 2024: Retina's Believe it or Not: Case-Based Examples and Real-World Treatment Strategies

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

VBS Board Moderators:

Yewlin E. Chee, MD
University of Washington
Department of Opthalmology
Seattle, WA

Anton Orlin, MD
Mid Atlantic Retina
Wills Eye Hospital
New York, NY

Aleksandra V. Rachitskaya, MD
Cleveland Clinic
Cole Eye Institute
Cleveland, OH

Camila Ventura, MD, PhD
Altino Ventura Foundation
HOPE Eye Hospital
Recife, Brazil

Panelists:

Fellows:

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty members and planning committee have the following financial relationships with ineligible companies.

Sruthi Arepalli, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie and Alimera Sciences.

Frederico Bermudes, MD, has had no financial relationships or affiliations with ineligible companies.

Gabriel Casthilho Sandoval Barbosa, MD, has had no financial relationships or affiliations with ineligible companies.

Yewlin E. Chee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon.

Carlos Miguel Córdoba Ortega, MD, has had no financial relationships or affiliations with ineligible companies.

Salvador García-Luna, MD, has had no financial relationships or affiliations with ineligible companies.

Chloe Khoo, MD, has had no financial relationships or affiliations with ineligible companies.

Priscilla Manni, MD, has had no financial relationships or affiliations with ineligible companies.

Anton Orlin, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Apellis Pharmaceuticals, Genentech, and Regeneron.

Ece Ozdemir Zeydanli, MD, FICO, FEBO, FRCSEd, has had no financial relationships or affiliations with ineligible companies.

Thanos Papakostas, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Beyeonics, EyePoint Pharmaceuticals, and Iveric Bio. Shareholder: Aldeyra.

D. Wilkin Parke III, MD, has had no financial relationships or affiliations with ineligible companies.

Aleksandra Rachitskaya, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Apellis Pharmaceuticals, Boehringer Ingelheim, EyePoint Pharmaceuticals, Iveric Bio, Ocular Therapeutix, Regeneron, Roche/Genentech, and Samsara Therapeutics. Speaker's Bureau: Apellis Pharmaceuticals, Genentech, Iveric Bio, and Regeneron.

Prethy Rao, MD MPH, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Bausch + Lomb, DORC, EyePoint Pharmaceuticals, Iveric Bio, and Vortex. Grant/Research Support: Regenxbio. Speaker's Bureau: Regeneron.

Meera Diana Sivalingam, MD, has had no financial relationships or affiliations with ineligible companies.

Matt Starr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Aldeyra, Allergan, Bausch + Lomb, BlephEx, Bruder Healthcare, CSI Dry Eye, Dompe, Essiri, EyeBio, Johnson & Johnson Vision, Kala Pharmaceuticals, Lumenis, Novaliq, Novartis, Oyster Point Pharma, Quidel, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, Trukera Medical, Versea Health, and Visionology. Grant/Research Support: Kala Pharmaceuticals. Shareholder: CSI Dry Eye, Essiri, and Visionology.

Beatriz Sayuri Takahashi, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Speaker's Bureau: Bayer and Roche.

Katherine E. Talcott, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera, Apellis Pharmaceuticals, Bausch + Lomb, Carl Zeiss Meditec, Eyepoint Pharmaceuticals, Genentech, Iveric Bio, Outlook Therapeutics, Regeneron, and Regenxbio. Grant/Research Support: Carl Zeiss Meditec, Regeneron, and Regenxbio. Speaker's Bureau: Carl Zeiss Meditec, Genentech, and Iveric Bio.

Joshua Uhr, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech and Regeneron. Shareholder: Alimera Sciences.

Tatiana Maria Vélez Osorio, MD, has had no financial relationships or affiliations with ineligible companies.

Camila Ventura, MD, PhD, has had no financial relationships or affiliations with ineligible companies.

Edward Wood, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Genentech, Pharming, and Regenxbio. Grant/Research Support: Coherus, EyeBio, Henlius, Opthea, Regenxbio, Unity, and Valo Health. Stock Options: Quadrant Eye. Speaker's Bureau: Iveric Bio. Patent: Vortex.

The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.